期刊文献+

乳腺浸润性导管癌组织中CAS蛋白表达的临床病理意义

Expression of CAS protein and its clinical significance in the invasive ductal carcinoma of the breast
下载PDF
导出
摘要 目的研究乳腺浸润性导管癌组织中细胞凋亡易感蛋白(CAS)表达的临床病理意义。方法选取乳腺浸润性导管癌53例、普通导管增生20例、异型导管增生20例、导管原位癌10例、正常乳腺组织14例,应用免疫组化方法观察CAS蛋白的表达,并探讨CAS与乳腺癌临床病理因素的关系,分析CAS和HER2、ER、PR以及ki-67指数的关系。结果 CAS在正常乳腺、普通导管增生、异型导管增生、导管原位癌、浸润性导管癌中的阳性率逐渐升高,分别为14.3%、25.0%、40.0%、60%、75.5%(P=0.000),CAS、HER2均与乳腺癌组织学分级、核分裂像、淋巴结转移有关;CAS评分与ki-67指数(r=0.439,P=0.003)和HER2评分(r=0.598,P=0.000)正相关。结论 CAS与乳腺癌的发生、发展、增殖、淋巴结转移有关,可能作为反映乳腺癌生物学行为的肿瘤标记物,CAS蛋白的表达和HER2有一定的相关性。 Objective To investigate the expression of cellular apoptosis susceptibility(CAS) and its clinical significance in the invasive ductal carcinoma(IDC) of the breast.Methods Immunohistochemical method was used to observe the expression of CAS in 53 cases of IDC,20 usual ductal hyperplasia(UDH),20 atypical ductal hyperplasia(ADH),10 ductal carcinoma in situ(DCIS),and 14 normal breast tissues.The correlations of CAS expression with HER2,ER,PR,and ki-67 index were analyzed.Results The positive rates of the CAS protein in normal breast tissues,UDH,ADH,DCIS and IDC were 14.3%,25.0%,40%,60%,and 75.5%,respectively(P0.001).The expressions of CAS and HER2 were positively correlated with histologic grade,mitotic activity,and lymph node metastasis.The positive expression of CAS was correlated with ki-67 index(r=0.439,P0.01) and HER2(r=0.598,P0.001).Conclusion High expression of CAS is closely correlated with the pathogenesis,progression and lymph node metastasis of breast carcinoma.CAS could be considered a marker of the biological behavior of breast carcinoma.Furthermore,CAS may be associated with HER2 expression.
出处 《中国组织化学与细胞化学杂志》 CAS CSCD 2011年第6期588-591,共4页 Chinese Journal of Histochemistry and Cytochemistry
关键词 乳腺肿瘤 细胞凋亡易感蛋白 免疫组织化学 Breast tumor Cellular apoptosis susceptibility Immunohistochemistry
  • 相关文献

参考文献13

  • 1Tang-Yi Tsao,Chin-Shaw Stella Tsai,Jai-Nien Tung,Shun-Liang Chen,Chia-Herng Yue,Ching-Fong Liao,Chi-Chao Wang,Ming-Chung Jiang.Function of CSE1L/CAS in the secretion of HT-29 human colorectal cells and its expression in human colon[J]. Molecular and Cellular Biochemistry . 2009 (1-2)
  • 2Ian E. Krop,Eric P. Winer.Ten years of HER2-directed therapy: still questions after all these years[J]. Breast Cancer Research and Treatment . 2009 (2)
  • 3Shiraki K,Fujikawa K,Sugimoto K,et al.Cellular ap-optosis susceptibility protein and proliferation in humanhepatocellular carcinoma. International Journal of Molecular Medicine . 2006
  • 4Ginestier C,Cervera N,Finetti P,et al.Prognosis andgene expression profiling of 20q13-amplified breast canc-ers. Clinical Cancer Research . 2006
  • 5Tung MC,Tsai CS,Tung JN,et al.Higher Prevalenceof Secretory CSE1L/CAS in Sera of Patients with Meta-staticCancer. Cancer Epidemiology Biomarkers and Prevention . 2009
  • 6Katherine E Ewings Kevin M Ryan.Hzf and hCAS/CSEIL: making the right choice in p53-mediated tumour suppression[J].Cell Research,2007,17(10):829-831. 被引量:3
  • 7Stella Tsai CS,Chen HC,Tung JN,etal.Serum cellu-lar apoptosis susceptibility protein is a potential prog-nostic marker for metastatic colorectal cancer. American Journal of Pathology . 2010
  • 8Jiang MC,Liao CF.CSE1/CAS overexpression inhibits the tumorigenicity of HT-29colon cancer cells. Journal of Experimental and Clinical Cancer Research . 2004
  • 9CF Liao,SF Luo,TY Shen,CH Lin,JT Chien,SY Du,MC Jiang.CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs. BMB Rep . 2008
  • 10Wellmann A,Flemming P,Behrens P,et al.High expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: correlation with tumor progression. International Journal of Molecular Medicine . 2001

二级参考文献10

  • 1Crighton D, Ryan KM. Splicing DNA-damage responses to tumour cell death. Biochim Biophys Acta 2004; 1705:3-15.
  • 2Samuels-Lev Y, O'Connor D J, Bergamaschi D, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8:781-794.
  • 3Bergamaschi D, Samuels Y, O'Neil N J, et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 2003; 33:162-167.
  • 4Budhram-Mahadeo VS, Bowen S, Lee S, et al. Bm-3b enhances the pro-apoptotic effects of p53 but not its induction of cell cycle arrest by cooperating in trans-activation ofbax expression. Nucleic Acids Res 2006; 34:6640-6652.
  • 5Coutts AS, La Thangue NB. The p53 response: emerging levels of co-factor complexity. Biochem Biophys Res Commun 2005; 331:778-785.
  • 6Das S, Raj L, Zhao B, et al. Hzf Determines Cell Survival upon Genotoxic Stress by Modulating p53 Transactivation. Cell 2007; 130:624-637.
  • 7Tanaka T, Ohkubo S, Tatsuno I, Prives C. hCAS/CSEIL Associates with Chromatin and Regulates Expression of Select p53 Target Genes. Cell 2007; 130:638-650.
  • 8Casolari JM, Brown CR, Komili S, West J, Hieronymus H, Silver PA. Genome-wide localization of the nuclear transport machinery couples transcriptional status and nuclear organization. Cell 2004; 117:427-439.
  • 9Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator ofglycolysis and apoptosis. Cell 2006; 126:107-120.
  • 10Crighton D, Wilkinson S, O'Prey J, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006; 126:121-134.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部